Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection?

Transpl Infect Dis. 2010 Dec;12(6):561-4. doi: 10.1111/j.1399-3062.2010.00580.x. Epub 2010 Oct 7.

Abstract

Organisms contained in probiotics are generally regarded as non-pathogenic and safe to administer. However, increasing reports of probiotic-associated infection raise concern over the safety of these products. We report a case of Lactobacillus empyema in a human immunodeficiency virus-infected lung transplant recipient receiving a probiotic containing Lactobacillus rhamnosus GG. We compare the epidemiology of Lactobacillus infections in heart and lung transplant recipients at our institution before and after the introduction of this probiotic, and discuss the potential mechanism for Lactobacillus within the probiotic to cause infections and disseminate.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Empyema, Pleural / epidemiology
  • Empyema, Pleural / microbiology*
  • Gram-Positive Bacterial Infections / epidemiology
  • Gram-Positive Bacterial Infections / microbiology*
  • Heart Transplantation / adverse effects*
  • Humans
  • Lacticaseibacillus rhamnosus / classification
  • Lacticaseibacillus rhamnosus / genetics
  • Lacticaseibacillus rhamnosus / isolation & purification
  • Lacticaseibacillus rhamnosus / pathogenicity*
  • Lung Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Probiotics / therapeutic use*
  • RNA, Ribosomal, 16S / genetics
  • Sequence Analysis, DNA

Substances

  • RNA, Ribosomal, 16S